Estimation of the Resource Utilization and Costs of Cytokine Release Syndrome Observed in the Transcend-NHL Clinical Trial: A Micro-Costing Study

Using data from the TRANSCEND-NHL trial, researchers analyzed the incidence of cytokine release syndrome as a treatment-related adverse event following CAR T-cell therapy. Their findings, presented at the 2018 American Society of Hematology Annual Meeting, showed that hospital and ICU length of stay are two key factors in the cost of CRS management, mainly for grade 3/4 CRS, demonstrating that dissimilarities in treatment can be costly.

Blood (ASH Abstract)